{"pmid":32369204,"title":"Hepatic involvement in COVID-19 patients: pathology, pathogenesis and clinical implications [Review].","text":["Hepatic involvement in COVID-19 patients: pathology, pathogenesis and clinical implications [Review].","During the clinical course of COVID-19, it has been observed that hepatic injury occurs in a significant proportion of patients, particularly in those with severe or critical illness. Mild increase in sinusoidal lymphocytic infiltration and multifocal hepatic necrosis are the main pathologic changes. Direct viral induced cellular injuries and potential hepatotoxicity from therapeutic drugs are two likely underlying mechanisms. In addition, preexisting chronic liver disease exacerbated during COVID-19, and COVID-19-related hyper-inflammatory reactions may contribute to liver injury as well. Further studies of additional autopsy cases will help clarifying these possibilities. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Yueying","Xiao, Shu-Yuan","32369204"],"abstract":["During the clinical course of COVID-19, it has been observed that hepatic injury occurs in a significant proportion of patients, particularly in those with severe or critical illness. Mild increase in sinusoidal lymphocytic infiltration and multifocal hepatic necrosis are the main pathologic changes. Direct viral induced cellular injuries and potential hepatotoxicity from therapeutic drugs are two likely underlying mechanisms. In addition, preexisting chronic liver disease exacerbated during COVID-19, and COVID-19-related hyper-inflammatory reactions may contribute to liver injury as well. Further studies of additional autopsy cases will help clarifying these possibilities. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Yueying","Xiao, Shu-Yuan"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369204","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25973","keywords":["covid-19","coronavirus","hepatotoxicity","jmv25973","liver injury","pathogenesis"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138496240189441,"score":9.490897,"similar":[{"pmid":32437004,"title":"Hepatic complications of COVID-19 and its treatment.","text":["Hepatic complications of COVID-19 and its treatment.","COVID-19 is highly contagious and has a variety of clinical manifestations, it can affect a number of other organs in addition to the lungs, and liver injury may occur. SARS-CoV-2 can cause liver injury through systemic inflammatory response syndrome (SIRS), cytokine storms, ischemia-reperfusion injury, side effects of treatment drugs, and underlying liver disease and can attack liver cells directly via ACE2. Clinical studies have found that liver injury in COVID-19 patients mainly manifests as abnormal liver biochemical indicators, but there have been no reports of liver failure caused by this disease. The number of COVID-19 patients with liver injury is increasing, and the incidence of liver injury in COVID-19 patients with severe disease are higher than in patients with mild disease. Liver injury may be a risk factor for progresses and worsens in patients with COVID-19, and it is necessary to pay attention to the occurrence of liver injury in the diagnosis and treatment of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Tian, Dandan","Ye, Qing","32437004"],"abstract":["COVID-19 is highly contagious and has a variety of clinical manifestations, it can affect a number of other organs in addition to the lungs, and liver injury may occur. SARS-CoV-2 can cause liver injury through systemic inflammatory response syndrome (SIRS), cytokine storms, ischemia-reperfusion injury, side effects of treatment drugs, and underlying liver disease and can attack liver cells directly via ACE2. Clinical studies have found that liver injury in COVID-19 patients mainly manifests as abnormal liver biochemical indicators, but there have been no reports of liver failure caused by this disease. The number of COVID-19 patients with liver injury is increasing, and the incidence of liver injury in COVID-19 patients with severe disease are higher than in patients with mild disease. Liver injury may be a risk factor for progresses and worsens in patients with COVID-19, and it is necessary to pay attention to the occurrence of liver injury in the diagnosis and treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Tian, Dandan","Ye, Qing"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437004","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26036","keywords":["covid-19","liver injury","mechanism","sars-cov-2"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667521393557766144,"score":229.74904},{"pmid":32291399,"title":"Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.","text":["Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.","Data on pathologic changes of the 2019 novel coronavirus disease (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed postmortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia. The patients' ages ranged from 59 to 81, including three males and one female. Each patient had at least one underlying disease, including immunocompromised status (chronic lymphocytic leukemia and renal transplantation) or other conditions (cirrhosis, hypertension, and diabetes). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes, all components of diffuse alveolar damage. Consolidation by fibroblastic proliferation with extracellular matrix and fibrin forming clusters in airspaces is evident. In one patient, the consolidation consists of abundant intra-alveolar neutrophilic infiltration, consistent with superimposed bacterial bronchopneumonia. The liver exhibits mild lobular infiltration by small lymphocytes, and centrilobular sinusoidal dilation. Patchy necrosis is also seen. The heart shows only focal mild fibrosis and mild myocardial hypertrophy, changes likely related to the underlying conditions. In conclusion, the postmortem examinations show advanced diffuse alveolar damage, as well as superimposed bacterial pneumonia in some patients. Changes in the liver and heart are likely secondary or related to the underlying diseases.","Mod Pathol","Tian, Sufang","Xiong, Yong","Liu, Huan","Niu, Li","Guo, Jianchun","Liao, Meiyan","Xiao, Shu-Yuan","32291399"],"abstract":["Data on pathologic changes of the 2019 novel coronavirus disease (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed postmortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia. The patients' ages ranged from 59 to 81, including three males and one female. Each patient had at least one underlying disease, including immunocompromised status (chronic lymphocytic leukemia and renal transplantation) or other conditions (cirrhosis, hypertension, and diabetes). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes, all components of diffuse alveolar damage. Consolidation by fibroblastic proliferation with extracellular matrix and fibrin forming clusters in airspaces is evident. In one patient, the consolidation consists of abundant intra-alveolar neutrophilic infiltration, consistent with superimposed bacterial bronchopneumonia. The liver exhibits mild lobular infiltration by small lymphocytes, and centrilobular sinusoidal dilation. Patchy necrosis is also seen. The heart shows only focal mild fibrosis and mild myocardial hypertrophy, changes likely related to the underlying conditions. In conclusion, the postmortem examinations show advanced diffuse alveolar damage, as well as superimposed bacterial pneumonia in some patients. Changes in the liver and heart are likely secondary or related to the underlying diseases."],"journal":"Mod Pathol","authors":["Tian, Sufang","Xiong, Yong","Liu, Huan","Niu, Li","Guo, Jianchun","Liao, Meiyan","Xiao, Shu-Yuan"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291399","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41379-020-0536-x","locations":["bronchopneumonia"],"topics":["Case Report"],"weight":1,"_version_":1666138494460755968,"score":202.27467},{"pmid":32455515,"title":"[Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results].","text":["[Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results].","Objective: To analyse the clinical history, laboratory tests and pathological data of a patient who suffered from novel coronavirus pneumonia(COVID-19) and provide reference for the clinical treatment of similar cases. Methods: Data of clinical manifestation, laboratory examination, bronchoscopy, echocardiography and cardiopulmonary pathological results were retrospectively reviewed in a case of COVID-19 with rapid exacerbation from mild to critical condition. Results: This patient hospitalized at day 9 post 2019 novel coronavirus(2019-nCoV) infection, experienced progressive deterioration from mild to severe at day 11, severe to critical at day 18 and underwent extracorporeal membrane oxygenation(ECMO) and continuous renal replacement therapy(CRRT) as well as heart lung transplantation during day 28-45 day post infection, and died on the second day post heart and lung transplantation. The patient had suffered from hypertension for 8 years. At the early stage of the disease, his symptoms were mild and the inflammatory indices increased and the lymphocyte count decreased continuously. The patient's condition exacerbated rapidly with multi-organ infections, and eventually developed pulmonary hemorrhage and consolidation, pulmonary hypertension, right heart failure, malignant ventricular arrhythmias, liver dysfunction, etc. His clinical manifestations could not be improved despite viral RNAs test results became negative. The patient underwent lung and heart transplantation and finally died of multi organ failure at the second day post lung and heart transplantation. Pathological examination indicated massive mucus, dark red secretions and blood clots in bronchus. The pathological changes were mainly diffused pulmonary hemorrhagic injuries and necrosis, fibrosis, small vessel disease with cardiac edema and lymphocyte infiltration. Conclusions: The clinical course of COVID-19 can exacerbate rapidly from mild to critical with lung, liver and heart injuries. Steadily increased inflammation indices are suggestive of irreversible disease progression and worse outcome. In the early stages of the disease, the progress of the disease should be closely observed and evaluated, and the factors related to the progress of the disease should be identified and managed.","Zhonghua Xin Xue Guan Bing Za Zhi","Jiang, S W","Gao, H","Wu, L","Wang, G W","Cen, F L","Li, J X","Feng, C","Wen, J M","Chen, Y","He, R L","Qiao, K","Wang, Y","Liu, Y X","Wang, Z Q","32455515"],"abstract":["Objective: To analyse the clinical history, laboratory tests and pathological data of a patient who suffered from novel coronavirus pneumonia(COVID-19) and provide reference for the clinical treatment of similar cases. Methods: Data of clinical manifestation, laboratory examination, bronchoscopy, echocardiography and cardiopulmonary pathological results were retrospectively reviewed in a case of COVID-19 with rapid exacerbation from mild to critical condition. Results: This patient hospitalized at day 9 post 2019 novel coronavirus(2019-nCoV) infection, experienced progressive deterioration from mild to severe at day 11, severe to critical at day 18 and underwent extracorporeal membrane oxygenation(ECMO) and continuous renal replacement therapy(CRRT) as well as heart lung transplantation during day 28-45 day post infection, and died on the second day post heart and lung transplantation. The patient had suffered from hypertension for 8 years. At the early stage of the disease, his symptoms were mild and the inflammatory indices increased and the lymphocyte count decreased continuously. The patient's condition exacerbated rapidly with multi-organ infections, and eventually developed pulmonary hemorrhage and consolidation, pulmonary hypertension, right heart failure, malignant ventricular arrhythmias, liver dysfunction, etc. His clinical manifestations could not be improved despite viral RNAs test results became negative. The patient underwent lung and heart transplantation and finally died of multi organ failure at the second day post lung and heart transplantation. Pathological examination indicated massive mucus, dark red secretions and blood clots in bronchus. The pathological changes were mainly diffused pulmonary hemorrhagic injuries and necrosis, fibrosis, small vessel disease with cardiac edema and lymphocyte infiltration. Conclusions: The clinical course of COVID-19 can exacerbate rapidly from mild to critical with lung, liver and heart injuries. Steadily increased inflammation indices are suggestive of irreversible disease progression and worse outcome. In the early stages of the disease, the progress of the disease should be closely observed and evaluated, and the factors related to the progress of the disease should be identified and managed."],"journal":"Zhonghua Xin Xue Guan Bing Za Zhi","authors":["Jiang, S W","Gao, H","Wu, L","Wang, G W","Cen, F L","Li, J X","Feng, C","Wen, J M","Chen, Y","He, R L","Qiao, K","Wang, Y","Liu, Y X","Wang, Z Q"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32455515","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3760/cma.j.cn112148-20200304-00155","keywords":["covid-19","clinical feature","extracorporeal membrane oxygenation","heart-lung transplantation","myocardial injury"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1667983494552223744,"score":195.5358},{"pmid":32478465,"title":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.","text":["First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.","BACKGROUND AND AIMS: Tocilizumab (TCZ; interleukine-6 receptor antagonist) has been proposed to treat severe forms of Coronavirus disease-19 (COVID-19) because interleukine-6 plays an important role in COVID-19-induced cytokine storm. Several clinical studies have shown very good effects of TCZ in patients with COVID-19, with a few minor side effects reported. Only eight serious liver injuries caused by TCZ were reported before being used in the treatment of patients with COVID-19. Considering the significantly increased use of TCZ for the treatment of COVID-19, we would like to warn of its rare but possible serious hepatotoxicity, especially when used together with other hepatotoxic drugs. METHODS: We describe a patient with COVID-19-induced cytokine storm who developed drug-induced liver injury associated with the use of TCZ. RESULTS: One day after TCZ administration, serum transaminase levels increased 40-fold. Nevertheless, TCZ had a positive effect on clinical and laboratory parameters in cytokine storm, with transaminases values normalizing in 10 days. CONCLUSIONS: This is the first reported case of DILI caused by TCZ in a COVID-19 patient. Intensive liver function monitoring is imperative in COVID-19 patients, because of frequent polypharmacy with potentially hepatotoxic drugs.","Liver Int","Muhovic, Damir","Bojovic, Jelena","Bulatovic, Ana","Vukcevic, Batric","Ratkovic, Marina","Lazovic, Ranko","Smolovic, Brigita","32478465"],"abstract":["BACKGROUND AND AIMS: Tocilizumab (TCZ; interleukine-6 receptor antagonist) has been proposed to treat severe forms of Coronavirus disease-19 (COVID-19) because interleukine-6 plays an important role in COVID-19-induced cytokine storm. Several clinical studies have shown very good effects of TCZ in patients with COVID-19, with a few minor side effects reported. Only eight serious liver injuries caused by TCZ were reported before being used in the treatment of patients with COVID-19. Considering the significantly increased use of TCZ for the treatment of COVID-19, we would like to warn of its rare but possible serious hepatotoxicity, especially when used together with other hepatotoxic drugs. METHODS: We describe a patient with COVID-19-induced cytokine storm who developed drug-induced liver injury associated with the use of TCZ. RESULTS: One day after TCZ administration, serum transaminase levels increased 40-fold. Nevertheless, TCZ had a positive effect on clinical and laboratory parameters in cytokine storm, with transaminases values normalizing in 10 days. CONCLUSIONS: This is the first reported case of DILI caused by TCZ in a COVID-19 patient. Intensive liver function monitoring is imperative in COVID-19 patients, because of frequent polypharmacy with potentially hepatotoxic drugs."],"journal":"Liver Int","authors":["Muhovic, Damir","Bojovic, Jelena","Bulatovic, Ana","Vukcevic, Batric","Ratkovic, Marina","Lazovic, Ranko","Smolovic, Brigita"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478465","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/liv.14516","keywords":["covid-19","sars-cov-2","drug-induced liver injury","hepatotoxicity","tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1668437834911973376,"score":194.52217},{"pmid":32403255,"title":"COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.","text":["COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.","The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted.","J Clin Med","Kukla, Michal","Skonieczna-Zydecka, Karolina","Kotfis, Katarzyna","Maciejewska, Dominika","Loniewski, Igor","Lara, Luis F","Pazgan-Simon, Monika","Stachowska, Ewa","Kaczmarczyk, Mariusz","Koulaouzidis, Anastasios","Marlicz, Wojciech","32403255"],"abstract":["The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted."],"journal":"J Clin Med","authors":["Kukla, Michal","Skonieczna-Zydecka, Karolina","Kotfis, Katarzyna","Maciejewska, Dominika","Loniewski, Igor","Lara, Luis F","Pazgan-Simon, Monika","Stachowska, Ewa","Kaczmarczyk, Mariusz","Koulaouzidis, Anastasios","Marlicz, Wojciech"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403255","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/jcm9051420","keywords":["covid-19","mers","sars","sars-cov-2","coronavirus","liver","pandemic"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1666802845321527296,"score":193.14726}]}